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because of premature mortality and
disability, adjusted for the severity of
C. Arandjus et al.1672as part of the routine clinical management of patients with COPD or chronic
bronchitis.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Globally, chronic obstructive pulmonary disease
(COPD) is one of the leading causes of morbidity
and mortality, and results in a substantial economic
and social burden.1 In the USA alone, the total cost
of COPD in 2004 was estimated to be $37.2 billion,
with direct medical costs accounting for $20.9
billion.2 In the UK, annual direct costs are
estimated at £819.42 per patient, with a total per
patient cost of £1639.08.3 By far the largest part of
all expenditure for patients with COPD are costs
related to hospitalization.2,4 COPD was ranked
eleventh as the leading cause of disability-adjusted
life years (DALYs)a lost worldwide in 2002, and was
expected to rise to fourth position by the year
2030.6
COPD exacerbations add to the burden of this
disease, and have a significant effect on morbidity,
mortality and healthcare expenditure. Economic
analyses indicate that exacerbations are a key
driver of secondary-care costs. Treatment aimed at
preventing exacerbations effectively, or preventing
or limiting hospitalizations, could significantly
reduce the clinical and economic impact of the
disease.4,7Oral vaccines
Bacterial infections are often implicated in COPD
exacerbations, and treatment with antibiotics is
common. The efficacy of antibiotics in treating
exacerbations has been debated. Their overuse has
been associated with increased cost and the
potential for increased microbial antibiotic resis-
tance.8 The oral administration of bacterial lysates
to stimulate immune defences has been used in
Europe and China for a number of years, and may
offer an alternative strategy for the prevention of
exacerbations.9,10 However, the mechanism of
action of these mucosal vaccines is not well
understood, and the GOLD guidelines do nothe sum of years of life lost
years of life lived with
disability’’.5recommend them as part of the routine manage-
ment of COPD or chronic bronchitis.1Mechanism of action
The constant exposure of the airways and lungs to
inhaled bacteria and toxins present a challenge to
the immune system. The ability of the airway
mucosa to distinguish between harmful and harm-
less antigens is important in defending against
pathogens and also in protecting against damage
caused by the body’s own inflammatory re-
sponses.11 It has been suggested that mucosal
vaccines, either killed whole-cell formulations or
agents containing antigens derived from several
strains of bacteria, may increase resistance to
infection by these organisms.11,13 The way in which
these oral vaccines may exert their effects is not
fully understood, but a number of possible mechan-
isms have been proposed. In animal models,
recognition of the orally administered bacteria by
gut-associated lymphoid tissue is followed by
trafficking of intestinally derived B- and T-cells to
bronchus-associated lymphoid tissue, and this may
lead to an immune response against these patho-
gens in the respiratory tract.14 Oral bacterial
extracts may also have non-specific immunomodu-
latory effects. Broncho-Vaxom (OM-85 BV), an
agent comprising extracts from eight bacterial
strains, has been shown to enhance the production
of tumour necrosis factor-a and interferon-g from
cultured human peripheral blood mononuclear
cells,15 to lead to activation of alveolar macro-
phages,16 and to stimulate bacterial killing by
polymorphonuclear leukocytes.17Reviews of oral vaccines
Systematic reviews are advantageous because
existing clinical trial evidence about a specific
topic can be assimilated and formally and objec-
tively appraised using set criteria in order to
establish generalizability of findings and consis-
tency of results.18 This is particularly valuable
when the primary trials are small and under-
powered to detect clinically meaningful treatment
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Table 1 Overview of reviews.20,21
Reference Participants Interventions Outcome measures
Foxwell et al.20 Adults with COPD or
recurrent acute
exacerbations of
chronic bronchitis
Orally administered
monobacterial NTHi
vaccine vs. lactose
placebo
 Incidence of acute
exacerbations of chronic
bronchitis
 Carriage level of NTHi in the
respiratory tract
 Numbers of prescriptions for
antibiotics during trial as
indication of severity of
exacerbations
Steurer-Stey et al.21 Adults with COPD or
chronic bronchitis
Orally administered
bacterial extract vs.
placebo or no
treatment
 Efficacy—including prevention
of exacerbations, duration of
exacerbations, improvement
as assessed by observers and
patients, hospitalisation
 Harm—adverse effects
COPD, chronic obstructive pulmonary disease; NTHi, nontypeable Haemophilus influenzae vaccine.
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cians to base their decisions on the best
available evidence; however, the inclusion of low-
quality or invalid trials results may bias results
and lead to an overestimation of treatment
effects.19 Systematic reviews, such as those under-
taken by the Cochrane Collaboration, seek to
overcome these problems by using a predefined,
explicit methodology to compile research findings.
This approach aims to reduce bias, improve
validity, and assist clinicians to make well-informed
decisions.
In recent years, two reviews have been under-
taken to evaluate the role of different oral mu-
cosal vaccines in the prevention of exacerbations,
including nontypeable Haemophilus influenzae
vaccine (NTHi), Broncho-Vaxom (OM-85BV), Luivac
(LW-50020), and SL-04 (Table 1).20,21 The pur-
pose of this current paper is to provide an over-
view of the reviews that have been completed
in this area and to evaluate whether the use
of these vaccines is likely to be clinically relevant
in the management of COPD and chronic
bronchitis.Haemophilus influenzae vaccines
A recent Cochrane review evaluated oral vaccines
of nontypeable H. influenzae.20Objectives
The objectives of the review were to evaluate the
effectiveness of oral whole-cell nontypeable NTHi
vaccines in protecting against acute exacerbations
of chronic bronchitis, and to determine the
relationship between efficacy of the vaccine and
carriage of NTHi in the respiratory tract.Study design
Studies included in the review were randomized-
controlled trials comparing the effects of an orally
administered NTHi vaccine with a placebo control
in adults with COPD or recurrent acute exacerba-
tions of chronic bronchitis.Outcome measures
The outcome measures for the review were the
incidence of acute exacerbations of chronic bron-
chitis, the numbers of prescriptions for antibiotics
and carriage levels of NTHi in the respiratory tract.
The duration of follow-up in the trials varied from
3–12 months. Analysis was intention-to-treat, with
additional information requested from the authors
of the primary trials as required. Differences in the
outcomes of the different trials were assessed for
heterogeneity using RevMan software.
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C. Arandjus et al.1674Review methods
Trials were located using comprehensive electronic
and manual search strategies with no language
restrictions, and independently selected by two
reviewers using the methods section only. The
search was restricted to published trials only;
however, unpublished data were gained from the
authors of the trials finally selected for review.
Despite using this search strategy, the reviewers do
not seem to have included any studies that they
were not aware of before undertaking the review.
Data were extracted and trial quality assessed
independently by three individual reviewers from
details of randomization, blinding of patients and
outcome assessment, and the number of patients
lost to follow-up.Description of selected studies
The review included six prospective, randomized,
double-blind, placebo-controlled trials, in which an
oral monobacterial NTHi vaccine was compared
against a placebo in age-matched individuals with
recurrent acute exacerbations of chronic bronchitis
(Table 2). The reviewers state that only trials in
which vaccine and placebo groups were overtly
matched on clinical grounds were included. Of the
six trials, five were conducted in Australia and one
in Papua New Guinea. The trials included a total of
440 adults aged between 19 and 93 years with
COPD22 or recurrent acute episodes of chronic
bronchitis.23–26 Five of the six trials were con-
ducted by the same investigators, and one of the
reviewers was an investigator in these trials.
All six trials used identical preparations and
vaccination regimens. In each trial, participants
were given a 3-day course of the vaccine or placebo
each month for 3 consecutive months, with each
course consisting of two tablets taken after break-
fast. The vaccine used consisted of 1011 formalin
killed NTHi enteric-coated tablets.
The studies were all randomized-controlled
trials, and the reviewers reported adequate quality
of the selected trials based on random assignment
and allocation concealment. Trials were generally
small, ranging in size from 40–109 participants.
None of the trials reported on consecutive patient
enrolment and, although four of the six trials
accounted for the numbers of participants lost to
follow-up, only one included a statement of how
dropouts were dealt with in the analysis.26 The
reviewers noted that all of the trials were analysed
on an intention-to-treat basis, although only one of
the original publications stated this.26The study population in the review was some-
what variable, and this may be important in terms
of vaccine efficacy. Groups mainly comprised men
in four of the six trials, and the age range between
participants was large, with median age ranging
from 46.3 to 73.1 years. The entry criteria and
definitions of these conditions differed between
trials. Although lung function was assessed at
baseline in all six trials, these data were part of
the selection criteria and used to classify severity
of disease in only one trial.26 The resulting study
population therefore comprised older patients with
established COPD and younger patients with less
evidence of airflow obstruction. A further problem
identified by the reviewers was the ability to match
the baseline incidence of acute infective exacer-
bations between exposure and control groups at
the beginning of the trials.
An unpublished trial conducted in Glasgow in the
UK was excluded because no pre-trial assessment
period was used to determine infection rates
before treatment. No other information about this
trial is provided in this review so it is difficult to
assess how appropriate it was to omit this trial.Review results and conclusions
All trials had broadly consistent findings. The
results of the review indicated a significant reduc-
tion in the incidence of acute episodes of chronic
bronchitis 0–3 months after oral vaccination with
NTHi (Poisson rate ratio 0.666; 95% confidence
interval [CI] 0.500–0.887; P ¼ 0.005). The inci-
dence was also reduced 6 months after vaccination.
However, the difference was not significant and the
effect had disappeared by 9 months. In terms of the
number needed to treat, the authors found a
reduction in incidence of one episode for every
five people vaccinated (assuming a baseline rate of
0.6 episodes per person), although this benefit rate
decreased over time. Of the six individual trials,
two found a significant reduction in the incidence
of acute bronchitic episodes in the vaccinated
group,22,26 and one found no significant difference
in the number of acute infections, but significantly
fewer episodes of acute wheezy bronchitis in those
who had been vaccinated.23 Although a trend was
observed towards a lower incidence of acute
bronchitic episodes in the remaining three trials,
none reached significance.24
Carriage levels of NTHi were measured in
samples obtained from throat swabs, sputum
samples, or both, at 12-week intervals and during
times of acute episodes. Results from the trials
showed NTHi levels were 32% lower in the
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C. Arandjus et al.1676vaccinated group at 3 months (Peto odds
ratio ¼ 0.68; 95% CI 0.41–1.11) and 43% lower at
6 months (Peto odds ratio ¼ 0.57; 95% CI
0.32–1.03). However, by 9 months, both vaccinated
and control groups had similar carriage levels.
Although a standard method for culturing bacteria
was used in all trials, different methods were used
to record results (i.e. absolute count or quadrant
methods), and this limits comparison of the data.
The need for antibiotic prescriptions was 58%
lower in the vaccinated group at 3 months (Peto
odds ratio 0.42; 95% CI 0.16–1.13) and 65% lower at
6 months (Peto odds ratio 0.35; 95% CI 0.16–0.75).
The authors concluded that this is further evidence
that use of an oral NTHi vaccine in patients with
recurrent acute exacerbations of chronic bronchitis
reduced the number and severity of exacerbations
for 3–6 months after vaccination, but this analysis
is based only on the two trials that collected this
information,22,36 and the difference was not statis-
tically significant.
The selected trials varied in length from 3–12
months. Although they all included the winter
months, they started at different times in the year.
One of the publications stated that the participants
were assessed at 3 and 6 months; however, in both
the original paper and the review, only the total
number of exacerbations between 0 and 6 months
is reported.23 It is not clear why information on the
number of exacerbations between 0 and 3 months
was not reported in the original publication or
included in the review. Only two trials collected
data for 12 months after vaccination, and this may
have reduced the likelihood of detecting any effect
beyond 6 months. The results of the review suggest
that vaccination with NTHi seems to confer a short-
term benefit in protecting against exacerbations in
people who are prone to recurrent acute bron-
chitis. However, caution needs to be exercised in
interpreting the findings because of the small
numbers of participants, the heterogeneity of the
patient populations, and questions about study
design.Purified bacterial extracts (Broncho-
Vaxom, Luivac & SL-04)
A systematic review published in 2004 evaluated
oral purified bacterial extracts.21
Objectives
The objectives of this review were to investigate
efficacy and harm of oral immunization withbacterial extracts in patients with chronic bron-
chitis and COPD.
Study design
The review included randomized-controlled trials
that compared an active oral bacterial extract with
placebo or control in adults with chronic bronchitis
and COPD. All of the products studied were lysates
made from several different types of bacteria.
Outcome measures
The primary outcome measure was prevention of
exacerbations as defined in the original studies.
Secondary outcome measures included the duration
of exacerbations, improvements of symptoms as
assessed by observers and patients, the rate of
hospitalization due to exacerbation and adverse
effects.
Review methods
Trials were located using electronic search strate-
gies with no language restrictions and by screening
the bibliographies of the trials and reviews that had
been identified. Manufacturers of bacterial ex-
tracts were also contacted. Screening and selection
of trials from those retrieved was carried out by
one reviewer. From the 71 trials retrieved, 58 were
excluded. The methodological quality of selected
trials was assessed independently by all four
reviewers on the basis of adequacy of patient
enrolment, sequence generation, allocation con-
cealment, blinding (patient, caregiver, outcome
assessment and data analysis), information about
how dropouts were handled, and use of intention-
to-treat analysis, with a score out of six assigned to
each study. Data were extracted by one reviewer
and cross checked by the others.
Description of selected studies
The review included 13 prospective, randomized,
placebo-controlled trials from seven countries,
including Canada, Egypt, France, Germany, Italy,
Switzerland and Yugoslavia. Inclusion criteria in-
cluded COPD (six trials), chronic bronchitis (10
trials), and more than three exacerbations within
the previous year (eight trials) (Table 3). A total of
1971 participants were included. Of the seven trials
that collected data on smoking, almost half the
patients were either current or ex-smokers, and, in
the five that measured lung function, participants
had mild-to-moderate COPD in four trials and
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C. Arandjus et al.1678severe COPD in one trial. The trials were all carried
out by different investigators, but seven trials
acknowledged sponsorship by a manufacturer.
Of the selected studies, 10 tested Broncho-
Vaxom (OM-85 BV), two tested Luivac (LW-50020)
and one tested SL-04. These vaccines vary in their
composition: OM-85 BV is an active lyophilized
extract of eight bacteria, including H. influenzae,
Diplococcus pneumoniae (Streptococcus pneumo-
niae), Klebsiella pneumoniae, Klebsiella ozaenae,
Staphylococcus aureus, Streptococcus pyogenes,
Streptococcus viridans, and Neisseria catarrhalis;
Luivac contains Staphylococcus aureus, Staphylo-
coccus mitis, Streptococcus pyogenes, Strepto-
coccus pneumoniae, Branhamella catarrhalis, Kleb-
siella pneumoniae, and H. influenzae.
The trials used varying vaccination regimens. For
preventative treatment, the manufacturers of OM-
85 BV recommend a dose of one 7mg capsule daily
taken on an empty stomach during 10 consecutive
days per month for 3 months (OM Pharma), but only
four of the 10 OM-85 BV trials used this regimen.
Both Luivac trials administered 3mg per day over a
3-month period. However, in one of the trials, this
period was interrupted by 1 month without treat-
ment. The trial of SL-04 used 1ml per day for 20
days per month for 3 months. Observation periods
in the trials also varied between 3 months and 1
year. As with the NTHi trials, the duration of follow-
up in the shorter trials may have been too short to
determine the duration of the treatment affect.
The methodological quality of the primary trials
was generally low. The analysis conducted by the
reviewers revealed a median score of 2, with only
one of the 13 trials attaining the maximum global
quality score of 6. Consecutive patient enrolment
and concealment of randomization were only
reported in two of the trials, and generation of a
random sequence in three. Although most of the
trials reported on blinding of the patient and
caregiver, less than half included a statement of
how dropouts were handled or intention-to-treat
analysis.
Trials were generally small, ranging from 19 to
381 participants. Comparison of patients was
difficult because studies differed in collecting and
reporting on baseline demographic data. However,
participants were predominantly male, with a wide
age range. One study reported participants as
young as 14 years and as old as 82 years. Again,
the inclusion of young participants suggests that a
heterogeneous patient population was studied.
This review included the PARI-IS study (Preven-
tion of Acute Respiratory Infections by an Immu-
nostimulant), which warrants further discussion as
the largest and most rigorous of the includedstudies.12 This trial investigated whether OM-85
BV could protect patients with COPD from acute
exacerbations as a result of respiratory tract
infection. Twelve centres in Montreal recruited
381 patients with COPD and randomly allocated
them to receive oral vaccination with either OM-85
BV or placebo. Patients were followed for 6 months,
and data were collected via diary card and through
monthly contacts with the research nurses. The
primary outcome was the occurrence of acute
exacerbations, and secondary outcomes included
the total number of exacerbations, hospitalization
for respiratory and general problems, change in
baseline respiratory symptoms and change in
quality of life. The duration of the exacerbations
was not reported. Although they were unable to
show a reduction in the occurrence of acute
exacerbations, the investigators found that OM-85
BV reduced the risk of hospitalization for a
respiratory problem and the length of stay in
hospital. The definition of an exacerbation included
an unscheduled doctor visit, treatment with anti-
biotics, or both. The authors report that partici-
pants in this study were quickly treated with
antibiotics when they had a change in symptoms,
and that this may have made it more difficult to
show an effect of treatment on the number of
exacerbations. Changes in dyspnoea, over the
course of the study, were measured with the
Oxygen Cost diagram. Dyspnoea reduced slightly
in the treatment group compared with placebo
(P ¼ 0.028).Review results and conclusions
This was a comprehensive and detailed review.
However, as the reviewers note, some important
limitations arise, mainly from the quality of the
primary studies. The limited size of most of the
trials reduces the power and increases the like-
lihood of detecting a treatment effect due to
chance. Given the low methodological quality of
the primary trials, overestimation of any treatment
effects is a risk.
Outcome measures varied considerably in the
primary trials, with a maximum of five trials
reporting on any of the same efficacy end points.
Only three of the 13 trials reported on the
prevention of exacerbations.12,27,28 Two of the
trials showed a beneficial effect with treatment,
and one showed no difference between treatment
and placebo over a 6-month observation period.
However, the reviewers noted a relationship
between study quality and treatment efficacy,
with conflicting results found by the two most
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from these two trials showed a relative risk of 0.83
(95% CI 0.55–1.25) in favour of active bacterial
extracts.
Three trials reported on the duration of exacer-
bations, and all showed a significantly shorter
average duration after treatment with active
extracts.28–30 Again the greatest benefit occurred
in a small, low-quality trial; however, analysis
of the data excluding this trial showed a weighted
mean difference of 2.7 days (95% CI 3.5
to 1.8).
Improvement of symptoms as assessed by ob-
servers was measured in five trials of between 3
and 12 months duration, all testing OM-85
BV.29,31–34 Differences between treatment and
control groups were statistically significant in
favour of bacterial extracts (RR 0.57; 95% CI
0.49–0.66). Two trials measured improvement of
symptoms as assessed by patients, one lasting 6
months and the other 12 months.32,33 Both trials
tested OM-85 BV, and found a greater improvement
reported by those receiving active extracts (RR
0.44; 95% CI 0.31–0.61).
Hospital admissions for respiratory problems
were measured in one trial only, with a 6-month
duration of follow-up, and were reported in 16.2%
of patients receiving OM-85BV and 23.2% of those
receiving a placebo (RR 0.70; 95% CI 0.46–1.06).12
Reported adverse effects included skin, urologic
and abdominal problems, and allergic reactions.
The occurrence of adverse gastrointestinal symp-
toms did not seem to differ significantly between
treatment and control groups; however, occurrence
of skin and urologic problems increased. Skin
itching or cutaneous eruptions were reported in
3.3% of patients receiving active extracts and in 1%
of controls (OR 2.94; 95% CI, 1.12–7.69). Lower
urinary-tract infections were reported in 8% of
patients receiving active extracts and in 3% of
controls (OR 2.62; 95% CI, 1.35–5.11).
A meta-analysis was carried out using
fixed-effect and random-effects models. The
authors concluded that, although there is no
strong evidence that oral bacterial extracts re-
duce the frequency of exacerbations, they do
seem to have a favourable effect in reducing the
severity of symptoms and duration of exacerba-
tions.Conclusion
The evidence on the use of bacterial extracts to
prevent exacerbations is inconclusive, but doessuggest that the use of oral multicomponent
vaccines may reduce the severity and duration of
acute episodes. Studies with the oral vaccines
against nontypeable H. influenzae have been
conducted in even fewer participants, but there is
some evidence for a short-term effect in reducing
exacerbations. From the limited data available,
these seem to be relatively safe interventions, with
the main reported problems of the multicomponent
vaccines being an increased risk of skin and
gastrointestinal problems, and lower urinary tract
infections. The main limitations of these reviews
relates largely to the small size and low methodo-
logical quality of many of the primary trials. The
primary trials vary in the end points they report on,
and, as a result, the outcome measures reported in
the reviews often depend on a handful of selected
trials.
The development of an effective mucosal vac-
cine potentially has a number of advantages,
including lowering of bacterial carriage levels in
the respiratory tract, decreasing the incidence and
severity of exacerbations, decreasing hospitaliza-
tions due to exacerbations, and reducing the need
for antibiotics. However, further research is needed
before oral vaccines can be included in the
standard clinical management of COPD and chronic
bronchitis. Large multi-centre trials using rigorous
methodology are needed to further investigate the
efficacy of this approach.
Practice points and research
directions
 Oral vaccines have been used in some
countries to prevent acute exacerbations
of chronic bronchitis.
 Vaccines comprise whole cell formulations
or agents containing antigens derived from
several strains of bacteria.
 The mechanism of action is not well under-
stood but they are thought to have immu-
nomodulatory effects.
 Reviews of nontypeable H. Influenzae and
of multicomponent oral vaccines suggest
these vaccines may reduce the number,
severity, duration, or both, of acute ex-
acerbations; however, many of the primary
trials on which they are based are small and
are methodologically flawed.
 Larger clinical trials are needed to investi-
gate efficacy before oral vaccination could
be recommended as part of the routine
clinical management of COPD.
ARTICLE IN PRESS
C. Arandjus et al.1680References1. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. Global
strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease: National Heart,
Lung, and Blood Institute and World Health Organi-
zation Global Initiative for Chronic Obstructive Lung
Disease (GOLD): executive summary. Respir Care 2001;46:
798–825.
2. National Heart Lung and Blood Institute. Morbidity and
mortality: 2004 chartbook on cardiovascular, lung, and
blood diseases. MD: US Department of Health and Human
Services; 2004.
3. Britton M. The burden of COPD in the UK: results from the
Confronting COPD survey. Respir Med 2003;97(suppl. C):
S71–9.
4. Wouters EF. Economic analysis of the confronting
COPD survey: an overview of results. Respir Med 2003;
97(suppl. C):S3–S14.
5. Murray CJ, Lopez AD. Evidence-based health policy—lessons
from the Global Burden of Disease Study. Science 1996;
274:740–3.
6. Mathers C, Loncar D. Updated projections of global
mortality and burden of disease, 2002–2030: data sources,
methods and results, vol 2006. Geneva: WHO; 2005.
7. Sullivan SD, Ramsey SD, Lee TA. The economic burden of
COPD. Chest 2000;117:S5–9.
8. Davies L, Hadcroft J, Mutton K, Earis JE, Kennedy N.
Antimicrobial management of acute exacerbation of chronic
airflow limitation. QJM 2001;94:373–8.
9. Ekberg-Jansson A, Larsson S, Lofdahl CG. Preventing
exacerbations of chronic bronchitis and COPD. BMJ 2001;
322:1259–61.
10. Li J, Zheng JP, Yuan JP, Zeng GQ, Zhong NS, Lin CY.
Protective effect of a bacterial extract against acute
exacerbation in patients with chronic bronchitis accompa-
nied by chronic obstructive pulmonary disease. Chin Med J
(Engl) 2004;117:828–34.
11. Pilette C, Durham SR, Vaerman JP, Sibille Y. Mucosal
immunity in asthma and chronic obstructive pulmonary
disease: a role for immunoglobulin A? Proc Am Thorac Soc
2004;1:125–35.
12. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A.
Effects of an immunostimulating agent on acute exacerba-
tions and hospitalizations in patients with chronic obstruc-
tive pulmonary disease. The PARI-IS Study Steering
Committee and Research Group. Prevention of acute
respiratory infection by an immunostimulant. Am J Respir
Crit Care Med 1997;156:1719–24.
13. Roth M, Block LH. Distinct effects of Broncho-Vaxom (OM-85
BV) on gp130 binding cytokines. Thorax 2000;55:678–84.
14. Kyd JM, Cripps AW. Killed whole bacterial cells, a mucosal
delivery system for the induction of immunity in the
respiratory tract and middle ear: an overview. Vaccine
1999;17:1775–81.
15. Wybran J, Libin M, Schandene L. Activation of natural
killer cells and cytokine production in man by bac-
terial extracts. Immunopharmacol Immunotoxicol 1989;11:
17–32.
16. Lusuardi M, Capelli A, Carli S, et al. Local airways immune
modifications induced by oral bacterial extracts in chronic
bronchitis. Chest 1993;103:1783–11791.
17. Nauek M, Matthys H, Emmons L. The immunomodulators
Broncho-Vaxom and Uro-Vaxom stimulate the bacterial
killing and oxidative metabolism of polymorphonuclear
leukocytes by the activation of phosphatidylinositol turn-
over. Int J Exp Clin Chemother 1991;4:1–11.18. Greenhalgh T. Papers that summarise other papers (sys-
tematic reviews and meta-analyses). BMJ 1997;315:672–5.
19. Verhagen AP, de Vet HC, de Bie RA, Boers M, van den Brandt
PA. The art of quality assessment of RCTs included in
systematic reviews. J Clin Epidemiol 2001;54:651–4.
20. Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae
oral whole cell vaccination for preventing acute exacerba-
tions of chronic bronchitis. In: The Cochrane Library, issue 2.
Chichester, UK: Wiley; 2003.
21. Steurer-Stey C, Bachmann LM, Steurer J, Tramer MR. Oral
purified bacterial extracts in chronic bronchitis and COPD:
systematic review. Chest 2004;126:1645–55.
22. Clancy R, Cripps A, Murree-Allen K, Yeung S, Engel M. Oral
immunisation with killed Haemophilus influenzae for pro-
tection against acute bronchitis in chronic obstructive lung
disease. Lancet 1985;2:1395–7.
23. Clancy RL, Cripps AW, Gebski V. Protection against recurrent
acute bronchitis after oral immunization with killed Hae-
mophilus influenzae. Med J Aust 1990;152:413–6.
24. Clancy RL, Cripps AW. Specific protection against acute
bronchitis associated with nontypeable Haemophilus influ-
enzae. J Infect Dis 1992;165(suppl. 1):S194–5.
25. Lehmann D, Coakley KJ, Coakley CA, et al. Reduction in the
incidence of acute bronchitis by an oral Haemophilus
influenzae vaccine in patients with chronic bronchitis in
the highlands of Papua New Guinea. Am Rev Respir Dis
1991;144:324–30.
26. Tandon MK, Gebski V. A controlled trial of a killed
Haemophilus influenzae vaccine for prevention of acute
exacerbations of chronic bronchitis. Aust N Z J Med 1991;21:
332–427.
27. Orcel B, Delclaux B, Baud M, Derenne JP. Preventive
effect of an immunomodulator, OM-85 BV, on acute exacer-
bations of chronic bronchitis in elderly patients. Preliminary
results at six months in 291 patients. Rev Mal Respir
1993;10:23–8.
28. Germouty J. Immunotherapy of recurrent respiratory infec-
tions. Double-blind study of a new immunomodulator in 60
patients [in French]. Rev Pneumol Clin 1986;42:207–13.
29. Cvoriscec B, Ustar M, Pardon R, et al. Oral immunotherapy
of chronic bronchitis: a double-blind placebo-controlled
multicentre study. Respiration 1989;55:129–35.
30. Djuric O, Mihailovic-Vucinic V, Stojcic V. Effect of Broncho-
Vaxom on clinical and immunological parameters in patients
with chronic obstructive bronchitis: a double-blind, place-
bo-controlled study. Int J Immunother 1989;5:139–43.
31. Keller R. Multicenter double-blind study of the action of
Broncho-Vaxom in chronic bronchitis. Schweiz Med Wo-
chenschr 1984;114:934–7.
32. Ahrens J. Clinical effects of oral immunotherapy. Atemw
Lungenkrkh 1983;9:424–7.
33. Khedr M. Clinical and immunological efficacy of Broncho-
Vaxom in chronic bronchitis: a double-blind study. Acta Ther
1993;19:49–60.
34. Messerli C, Michetti F, Sauser-Hall P, et al. Effect of a
bacterial lysate (Broncho-Vaxom) in the therapy of chronic
bronchitis: multi-center double-blind clinical trial. Rev Med
Suisse Romande 1981;101:143–6.
35. Fischer H, Eckenberger HP, van Aubel A, et al. Pra¨vention
von Infektrezidiven der oberen und unteren Luftwege [in
German]. Atemw Lungenkrkh 1992;18:146–55.
36. Orlandi O, Bruna S, Bagnasco G. Immunostimulation treat-
ment with a bacteriolysate in recurring bacterial infections
in chronic bronchitics. Min Pneumol 1983;22:461–4.
37. Rutishauser M, Pitzke P, Grevers G, van Aubel A, Elsasser U,
Kammereit A. Use of a polyvalent bacterial lysate in patients
ARTICLE IN PRESS
Oral bacterial vaccines in COPD and chronic bronchitis 1681with recurrent respiratory tract infections: results of a
prospective, placebo-controlled, randomized, double-blind
study. Adv Ther 1998;15:330–41.
38. Tag El Din M, Ashmawi S, Emam WEM. Effect of a polyvalent
bacterial extract, Broncho-Vaxom, in the prophylaxis ofacute exacerbations of chronic bronchitis. Eur J Clin Res
1993;4:99–105.
39. Keller R, Hinz G. Effect of an oral polyvalent bacterial lysate
(Broncho-Vaxom) in chronic bronchitis [in German]. Prax
Klin Pneumol 1984;38:225–8.
